NEW YORK (GenomeWeb News) – Two investment banks today initiated coverage of Veracyte with Outperform ratings on the company's stock.

The coverage initiation by Cowen & Co., and Leerwink Swann follows Veracyte's announcement on Monday that revenues for its third quarter rose 75 percent year over year, as well as the South San Francisco, Calif.-based company's initial public offering earlier this month.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.